Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia

International Urology and Nephrology

Volumn 42, Issue 1, 2010, Pages 7-12

  Lo, K L ^a   Chan, M C K ^a   Wong, A ^a   Hou, S M ^a   Ng, C F ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acute urinary retention; Alpha adrenergic receptor blocker; Benign prostate hyperplasia; Trial without catheter

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PROSTATE SPECIFIC ANTIGEN; TERAZOSIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE DURATION; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; ORGAN SIZE; PROGNOSIS; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROTEIN BLOOD LEVEL; RISK FACTOR; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URETHRAL CATHETERIZATION; URINE RETENTION; URINE VOLUME;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY RETENTION;

EID: 77950918163     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9572-7     Document Type: Article

References (22)

1. SJ Berry DS Coffey PC Walsh, et al. 1984 The development of human benign prostatic hyperplasia with age J Urol 132 3 474 479 1:STN:280: DyaL2c3pt1CrtQ%3D%3D 6206240 (Pubitemid 14026148)
2. PSF Chan WS Wong LW Chan, et al. 1996 Can terazosin (alpha-blocker) relieve acute urinary retention and obviate the need for an indwelling urethral catheter? Br J Urol 77 Suppl 1 7
3. SA McNeill TB Hargreave C Geffriaud-Ricouard, et al. 2001 Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin Urology 57 3 459 465 10.1016/S0090-4295(00)01021-9 1:STN:280:DC%2BD3M3islKitQ%3D%3D 11248620 (Pubitemid 32192975)
4. SA McNeill TB Hargreave CG Roehrborn, et al. 2005 Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study Urology 65 1 83 90 10.1016/j.urology.2004.07.042 1:STN:280:DC%2BD2M%2FktFeiug%3D%3D 15667868 (Pubitemid 40169610)
5. V Palit T Shah CS Biyani, et al. 2005 Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention Int Urol Nephrol 37 3 507 510 10.1007/s11255-004-4709-1 1:CAS:528:DC%2BD2MXht1GisrnK 16307331 (Pubitemid 41762508)
6. M Caine 1986 The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy J Urol 136 1 1 4 1:STN:280: DyaL283islOrug%3D%3D 2423716 (Pubitemid 16059581)
7. AUA Practice Guidelines Committee 2003 AUA guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations J Urol 170 2 530 547 10.1097/01.ju.0000078083.38675.79
8. WK Mebust HL Holtgrewe AT Cockett, et al. 1989 Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3, 885 patients J Urol 141 2 243 247 1:STN:280:DyaL1M7htFWmsA%3D%3D 2643719
9. JD McConnell CG Roehrborn OM Bautista, et al. 2003 Medical therapy of prostatic symptoms (MTOPS) research group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 25 2387 2398 10.1056/NEJMoa030656 1:CAS:528:DC%2BD3sXpvFGqt7s%3D 14681504 (Pubitemid 37542987)
10. M Caine A Pfau S Perlberg 1976 The use of alpha-adrenergic blockers in benign prostatic obstruction Br J Urol 48 4 255 263 10.1111/j.1464-410X.1976. tb03013.x 1:STN:280:DyaE2s%2FgtV2ksg%3D%3D 61054
11. A McNeill TB Hargreave Members of the ALFAUR study group 2004 Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention J Urol 171 6 2316 2320 10.1097/01.ju.0000127743.80759.7a 1:CAS:528: DC%2BD2cXkvVWhsrc%3D 15126812 (Pubitemid 38625461)
12. M Franciosi WJ Koff EL Rhoden 2007 Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS) Int Urol Nephrol 39 3 877 971 10.1007/s11255-006-9148-8 (Pubitemid 47365399)
13. CG Roehrborn MP Malice TJ Cook CJ Girman 2001 Clinical predictors of spontaneous acute retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials Urology 58 2 210 216 10.1016/S0090-4295(01)01155-4 1:STN:280:DC%2BD3MvksVertA%3D%3D 11489703 (Pubitemid 32728058)
14. Roehrborn CG for the ALTESS study group 2006 Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute retention: results of a 2-year placebo-controlled study BJU Int 97 4 734 741 10.1111/j.1464-410X.2006.06110.x (Pubitemid 43383505)
15. AS McNeill S Rizvi DJ Byrne 2004 Prostate size influences the outcome after presenting with acute urinary retention BJU Int 94 4 559 562 10.1111/j.1464-410X.2004.05000.x 15329112 (Pubitemid 39256480)
16. CG Roehrborn R Bruskewitz GC Nickel, et al. 2000 Urinary retention in patients with BPH treated with Finasteride or Placebo over 4 years Eur Urol 37 5 528 536 10.1159/000020189 1:STN:280:DC%2BD3c3ivFKluw%3D%3D 10765090
17. SA McNeil 2001 Does acute urinary retention respond to alpha-blockers alone? Eur Urol 39 suppl 6 7 12 10.1159/000052593 (Pubitemid 32304730)
18. JD McConnell R Bruskewitz P Walsh, et al. 1998 The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group N Engl J Med 338 557 563 10.1056/NEJM199802263380901 1:CAS:528:DyaK1cXhsF2ktr8%3D 9475762 (Pubitemid 28114643)
19. F Debruyne J Barkin P van Erps M Reis TLJ Tammela C Roehrborn 2004 Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia Eur Urol 46 4 488 494 10.1016/j.eururo.2004.05.008 1:CAS:528:DC%2BD2cXovF2ku7Y%3D 15363566 (Pubitemid 39200858)
20. P Boyle AL Gould CG Roehrborn 1996 Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials Urology 48 3 398 405 10.1016/S0090-4295(96)00353-6 1:STN:280:DyaK28zpslGquw%3D%3D 8804493 (Pubitemid 26317480)
21. CG Roehrborn JD McConnell M Lieber, et al. 1999 Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia Urology 53 3 473 480 10.1016/S0090-4295(98)00654-2 1:STN:280:DyaK1M7psVSgsQ%3D%3D 10096369 (Pubitemid 29136187)
22. AK Patel CR Chapple 2008 Medical management of lower urinary tract symptoms in men: current treatment and future approaches Nat Clin Pract Urology 5 4 211 219